FOLD

NEUTRALM&A

Amicus Therapeutics, Inc.

2026-04-15

Price

$14.46

+0.00%

Score12.0Top Tier

Signals5/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 6

Volume1.3xvs 20d avg

Analysis

The price action in Amicus Therapeutics (FOLD) is entirely dictated by its pending $4.8 billion all-cash acquisition by BioMarin Pharmaceutical at $14.50 per share. The technical signals—ALPHA_MALE, QUIET_STORM, and STEADY_CLIMB—are mechanically triggering off the stock's exceptionally low 1.9% realized volatility as it pins just pennies below the buyout price. This microscopic 4-cent arbitrage spread reflects supreme market confidence in the deal's imminent completion in Q2 2026. Furthermore, the current RISK_ON macro regime, characterized by ultra-tight high-yield credit spreads (0.81%), provides high conviction that financing and systemic risks to the merger are virtually non-existent.

Fired Signals

ALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSPERFECT STACKBARGAIN HUNTER

Key Takeaways

Actionable Thesis: FOLD is a pure merger arbitrage vehicle trading at $14.46, offering a highly probable but capped 4-cent upside to the $14.50 BioMarin cash offer.
Key Risk: The asymmetric tail risk of unexpected FTC/antitrust regulatory pushback or a last-minute breakdown in the merger agreement.
What to Watch: Monitor final regulatory clearance updates and shareholder vote confirmation ahead of the anticipated Q2 2026 closing.

← Back to 2026-04-15 View Full FOLD History →Yahoo Finance &nearr;